China’s New Pharmaceutical Trial Data Protection Regime: More Than an IP Reform

For years, pharmaceutical companies viewed China as a market where commercial opportunity often outpaced intellectual property protection. While reforms such as the Marketing Authorization Holder (MAH) system, accelerated review pathways, and patent linkage narrowed that gap, uncertainty around regulatory data protection remained one of the final missing pieces of China’s innovation framework.

The new Pharmaceutical Trial Data Protection Measures may therefore represent more than a procedural regulatory update. They signal China’s intention to compete not only for product launches, but increasingly for earlier-stage development, first indications, and innovation investment.

The strategic question is no longer whether China offers a data protection framework. The question is whether the framework is now sufficiently predictable to influence where companies choose to develop, file, and commercialize innovative medicines.

On May 15, 2026, the National Medical Products Administration (NMPA) issued “Announcement No. 47 of 2026,” formally promulgating the “Measures for the Implementation of Pharmaceutical Trial Data Protection” (the “Implementation Measures”). The rules took effect immediately.

For international pharmaceutical companies, this is not a procedural footnote. It is a structural shift in how exclusivity works in China – one that directly affects competitive positioning, filing timelines, licencing strategy, and the economics of launching innovative products in one of the world’s largest pharmaceutical markets.

Context: Why This Framework Matters

Data protection, sometimes called data exclusivity, prevents a generic or biosimilar applicant from relying on the originator’s undisclosed trial data to obtain regulatory approval without the originator’s consent during a defined exclusivity period. It forms an important component of pharmaceutical innovation frameworks in major markets including the United States, European Union, and Japan, and is linked to obligations concerning protection of undisclosed test data under the TRIPS Agreement.

China has had data protection provisions on paper since 2002, but without a comprehensive implementation mechanism. The result was uncertainty for innovative drug developers: legal principles without a clearly defined regulatory pathway.

The 2026 Implementation Measures fundamentally change that position by establishing eligibility criteria, application procedures, review mechanisms, and enforceable restrictions on competing applications.

These measures are also the second major pillar of China’s evolving pharmaceutical IP framework, following the patent linkage regime introduced in 2021. Together, the two systems strengthen the protection environment for innovative medicines and move China closer to regulatory approaches seen in several mature pharmaceutical markets.

Transitional Filing Requirements for Pending Applications

The NMPA paired the new framework with short transitional filing deadlines for companies with applications already in the pipeline.

For drug registration applications accepted before May 15, 2026, where technical review has not yet been completed, applicants seeking pharmaceutical trial data protection must submit an application to the NMPA Center for Drug Evaluation (CDE) within 15 working days of the announcement date, together with supporting materials. Failure to apply within that period will be deemed a waiver of pharmaceutical trial data protection.

The announcement also addresses situations in which review timelines are close to expiring. Where fewer than 20 days remain in the technical review period, the CDE may suspend the review clock while it forms a preliminary opinion regarding data protection eligibility. Once technical review is completed, the CDE will submit its preliminary opinion and review materials to the NMPA for further handling under the Implementation Measures.

Administrative Approval Stage Applications Also Included

The Implementation Measures also apply to drug registration applications that had already entered the administrative approval stage before May 15, 2026, but had not yet been approved.

In those cases, applicants meeting the protection criteria must likewise submit data protection applications within 15 days of the announcement.

The NMPA further stated that, from the date of the announcement until publication of relevant protection information on the CDE website, drug registration applications relying on such protected data may neither be accepted nor approved.

NMPA Policy Interpretation Clarifies Key Data Protection Concepts

Alongside the Implementation Measures, the NMPA issued a detailed policy interpretation addressing several core concepts embedded in the new framework, including the meanings of “undisclosed,” “self-obtained,” and “reliance.” Together, these interpretations provide important insight into how the agency is likely to administer the regime in practice.

“Undisclosed” Data Remains Protected Even if Partially Published

According to the NMPA, pharmaceutical trial data may still qualify as “undisclosed” even if portions of the data have already been made public.

The policy interpretation states that “undisclosed” means the relevant trial data have not been fully disclosed. As a result, partial publication of summaries or limited portions of trial data does not necessarily eliminate eligibility for protection.

Protection Covers Self-Generated, Commissioned, Purchased, and Exclusively Licensed Data

The term “self-obtained” was interpreted broadly. According to the NMPA, eligible data may include:

• Studies conducted directly by the applicant
• Commissioned studies
• Data acquired through purchase
• Exclusively licensed data

This clarification may be particularly relevant for multinational pharmaceutical companies relying on global development partnerships, licensing structures, or cross-border data arrangements. 

NMPA Defines “Reliance” by Generic and Improved Drug Applicants

The policy interpretation also clarifies the meaning of “reliance” under the new framework. 

According to the NMPA, reliance occurs where another applicant cites or relies upon trial data submitted by the marketing authorization holder (MAH) of an approved originator drug in support of an application for an improved new drug or generic drug without repeating the same trials.

The interpretation notes that improved new drugs and generics commonly rely on supplementary evidence, bioequivalence studies, or related approaches instead of conducting full clinical trials independently.

Scope of Potentially Protected Pharmaceutical Trial Data

The policy interpretation adopts a broad description of the pharmaceutical trial data potentially eligible for protection.

According to the NMPA, protected data generally include pharmaceutical, nonclinical, and clinical trial data submitted to demonstrate a drug’s safety, efficacy, and quality controllability.

Pharmaceutical Data Potentially Eligible for Protection

The policy interpretation states that pharmaceutical data may include:

• Active pharmaceutical ingredient (API) and formulation studies
• Manufacturing process information
• Quality standards and analytical methods
• Stability studies
• Packaging compatibility studies

Nonclinical and Clinical Data Also Covered

The NMPA further states that protected data may include nonclinical study data such as:

• Pharmacology studies
• Pharmacokinetics studies
• Toxicology studies
• Safety pharmacology studies

Clinical data potentially eligible for protection include:

• Early-stage clinical trial data (Phase I/II)
• Pivotal clinical trial data (Phase III)

The NMPA stated that the Implementation Measures were developed with reference to international regulatory experience.

Certain Categories of Data Remain Excluded

The policy interpretation also clarifies that not all pharmaceutical study data qualify for protection under the new framework:

• Bioavailability (BA) data generally are not protected
• Bioequivalence (BE) data generally are not protected
• Vaccine immunogenicity data generally are not protected

The agency explained that such data does not independently generate new evidence of safety or efficacy for purposes of pharmaceutical trial data protection.

Traditional Chinese Medicines Governed Separately

The NMPA also clarified that traditional Chinese medicines (TCMs) are not covered by this pharmaceutical trial data protection system because they are regulated under separate rules governing protection of traditional Chinese medicine varieties.

Special Provisions for Overseas-Originator Drugs

The Implementation Measures and accompanying policy interpretation contain several provisions specifically relevant to overseas-originator pharmaceutical products.

Six-Year Protection for Certain Overseas-Originator Applications

The policy interpretation addresses situations where an originator drug has already been marketed overseas but has not yet been marketed in China, and where a new indication first filed in China has not been approved anywhere in the world.

According to the NMPA, these applications are formally classified as improved new drugs, although applicants must still submit comprehensive trial data demonstrating safety, efficacy, and quality controllability.

The policy interpretation states that these applications may receive six years of pharmaceutical trial data protection under Article 5 of the Implementation Measures. The protected scope includes all trial data submitted in support of the marketing authorization application.

For multinational pharmaceutical companies pursuing simultaneous or closely coordinated global launches, this provision may significantly increase the strategic value of early China filings.

From a policy perspective, this may be one of the clearest signals yet that regulators are seeking to encourage earlier integration of China into global development and filing strategies rather than positioning the market solely as a post-approval expansion opportunity.

Subsequent Indications May Receive Four Years of Protection

For subsequent indication expansions involving already protected drugs, Article 6 may provide four years of protection for new clinical trial data demonstrating significant clinical advantages over known active ingredients or approved biologics.

However, the policy interpretation states that BA, BE, and vaccine immunogenicity data remain excluded from this protection scope.

First-to-File Generics May Receive Three Years of Protection

A third tier, less discussed but directly relevant for generics strategy, provides three years of data protection for the first generic approved for overseas approved but domestically unavailable originator drugs (Category 3 and 5.2 chemical drugs, or Category 3.2 biologics).

During that period, the NMPA will not approve subsequent generic applications relying on the same protected data without the holder’s consent. Companies monitoring reference drug pipelines and originator companies planning defensive exclusivity strategies should factor this tier into their planning.

Domestic Manufacturing Transfers May Preserve Existing Protection

The NMPA also addressed situations where overseas-manufactured originator drugs are transferred to domestic manufacturing in China.

According to the policy interpretation, where the originator drug has already obtained pharmaceutical trial data protection, other applicants may not rely on the protected data during the protection period without the holder’s consent.

The interpretation further states that the term “holders” includes both the holder of the imported originator drug and the holder of the domestically manufactured originator drug.

A domestic manufacturing MAH seeking such protection must obtain authorization from the original originator drug holder. This clarification may prove particularly important for multinational companies localizing manufacturing operations in China while seeking to maintain continuity of exclusivity protections.

CDE Issues Supporting Procedures and Filing Guidance

To support implementation, the Center for Drug Evaluation (CDE) simultaneously released “CDE Notice [2026] No. 158,” establishing the “Working Procedures for Pharmaceutical Trial Data Protection.”

The CDE also issued “CDE Notice [2026] No. 159,”which addresses application materials for drugs already approved or under review before issuance of the Implementation Measures.

Strategic Implications for International Pharmaceutical Companies

The new pharmaceutical trial data protection framework is likely to affect regulatory strategy, lifecycle management, and market entry planning for innovative pharmaceutical products in China.

The framework introduces several considerations that may warrant reassessment of existing regulatory, development, and lifecycle management strategies.

Based on the structure of the Implementation Measures and the accompanying policy interpretation, pharmaceutical companies should be assessing: 

• Whether pending or future products may qualify for pharmaceutical trial data protection
• Transitional filing opportunities for applications already under review or approved
• The potential impact of protection periods on generic competition timelines
• Lifecycle management strategies involving new indications or supplemental applications
• Coordination of China approvals with simultaneous global development programs
• Structuring of licensing, commissioned research, and cross-border data arrangements

The framework may be particularly relevant for overseas-originator products entering China for the first time, multinational companies pursuing new indications through global clinical development programs, and companies with applications currently in the NMPA pipeline that have not yet assessed transitional filing eligibility.

Closing Observation

The significance of the new framework extends beyond exclusivity periods themselves. By introducing a defined mechanism for obtaining and enforcing trial data protection, China has reduced one of the longstanding areas of uncertainty cited by innovative pharmaceutical companies.

Whether the framework ultimately changes development sequencing, licensing behavior, or China filing priorities remains to be seen. However, together with broader pharmaceutical policy reforms introduced in recent years, it reinforces China’s ambition to play a larger role in pharmaceutical innovation rather than serving solely as a destination market for products developed elsewhere.

For companies seeking guidance on China’s new pharmaceutical trial data protection framework, regulatory exclusivity strategy, or product lifecycle planning, contact Cisema today.

Further Information 

Explore Cisema’s Pharmaceutical Consulting services 

References 

• CDE Notice on Data Protection Filing Requirements for Drug Applications Approved or Under Review Before Issuance of the Measures for the Implementation of Pharmaceutical Trial Data Protection (CDE Notice [2026] No. 159) ‍
• NMPA Announcement on Issuing the Measures for the Implementation of Pharmaceutical Trial Data Protection (Announcement No. 47 of 2026)  
• CDE Notice on Issuing the Working Procedures for Pharmaceutical Trial Data Protection (CDE Notice [2026] No. 158)  
• Policy Interpretation of the Measures for the Implementation of Pharmaceutical Trial Data Protection  

‍